Early research (Phase 1)Study completedNCT03565445
What this trial is testing
ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors
Who this might be right for
Advanced Solid Tumors
Astellas Pharma Global Development, Inc. 190